NVS - Week In Review: Agilent Pays $250 Million To Acquire ACEA And Its Cell Therapy Analyzer
Deals And Financings
ACEA Biosciences, a San Diego company with R&D and manufacturing facilities in Hangzhou, will be acquired by Agilent (NYSE: A) for $250 million in cash (see story). ACEA has developed the xCELLigence® cell therapy analysis device intended for academic and biopharma researchers. The device is used in immuno-oncology, pre-clinical drug discovery and basic academic research. In 2015, ACEA raised $30 million from China investors Qiming and Lilly Asia Ventures. Agilent develops and sells laboratory equipment.
Zhejiang Anglikang Pharmaceutical, headquartered in Shengzhou, has been approved to stage an $87 million IPO on